ind-application

# IND Application

Drafts a complete IND application under 21 CFR Part 312 for FDA authorization to begin human clinical trials.

## Prerequisites

Collect before drafting:

1. **Drug substance/product info** — chemical name, code designation, structural formula, mechanism of action
2. **Nonclinical reports** — pharmacology, toxicology, PK/PD data
3. **CMC data** — manufacturing process, specifications, stability, certificates of analysis
4. **Clinical protocol(s)** — design, objectives, endpoints, statistical analysis plan
5. **Investigator info** — CVs, Form FDA 1572, clinical site details
6. **Prior human experience** (if any) — foreign trials, literature, compassionate use
7. **IRB documentation** — approval letters or submission plans, informed consent forms

## Quick Start

1. Confirm trial phase (I/II/III) — this drives CMC depth and nonclinical requirements
2. Complete Form 1571 cover sheet
3. Draft sections in 21 CFR 312.23(a) order (see below)
4. Cross-reference all nonclinical citations to specific IND sections
5. Run checklists for Form 1571, IB, protocol, and environmental assessment

## IND Section Order (21 CFR 312.23(a))

| # | Section | Reference |
|---|---------|-----------|
| 1 | Cover Sheet — FDA Form 1571 | 312.23(a)(1) |
| 2 | Table of Contents — mirror regulatory numbering | 312.23(a)(2) |
| 3 | Introductory Statement — rationale, therapeutic purpose, investigational plan | 312.23(a)(3) |
| 4 | Investigator's Brochure — safety, efficacy, pharmacology, known risks | 312.23(a)(5) |
| 5 | Clinical Protocol(s) — design, dosing, safety monitoring, statistical plan | 312.23(a)(6) |
| 6 | CMC: Drug Substance — synthesis, specs, stability | 312.23(a)(7) |
| 7 | CMC: Drug Product — formulation, controls, container/closure, stability | 312.23(a)(7) |
| 8 | Pharmacology/Toxicology — PK, acute/chronic tox, repro tox, genotox | 312.23(a)(8) |
| 9 | Previous Human Experience — prior clinical data, foreign trials, literature | 312.23(a)(9) |
| 10 | Additional Information — IRB approvals, consent, investigator qualifications | 312.23(a)(10) |

## Key Checklists

### Form 1571

- [ ] Sponsor name, address, contact
- [ ] Drug name and code designations
- [ ] Trial phase (I, II, III)
- [ ] IND number (amendment) or "Initial"
- [ ] Serial number
- [ ] Indication(s) under investigation
- [ ] List of enclosed sections
- [ ] Authorized signature with date

### Investigator's Brochure

- [ ] Physical/chemical/pharmaceutical properties
- [ ] Nonclinical pharmacology summary
- [ ] Nonclinical PK and metabolism
- [ ] Nonclinical toxicology (tabulate: species, route, duration, NOAEL, findings)
- [ ] Clinical experience summary (if applicable)
- [ ] Known/anticipated adverse effects and precautions

### Clinical Protocol

- [ ] Title, protocol number, version/date
- [ ] Primary and secondary objectives
- [ ] Study design and phase
- [ ] Inclusion/exclusion criteria
- [ ] Dosing regimen with rationale
- [ ] Efficacy and safety endpoints
- [ ] Stopping rules and dose-limiting toxicity definitions
- [ ] Safety monitoring plan (AE reporting, DSMB if applicable)
- [ ] Statistical analysis plan with sample size justification

## Phase-Appropriate CMC Depth

| Phase | Drug Substance | Drug Product | Stability |
|-------|---------------|-------------|-----------|
| I | Synthetic route, preliminary specs, structure confirmation | Formulation description, basic controls | Abbreviated (cover trial duration) |
| II | Refined process, tightened specs, impurity profiles | Validation initiated, expanded controls | 6+ months accelerated + long-term |
| III | Full process validation, complete characterization | Full cGMP, container/closure validation | ICH-compliant program |

## Nonclinical Study Table Format

For each study, tabulate: study type, test facility (with GLP status), species/strain, route, dose levels, duration, NOAEL/NOEL, key findings, relevance to clinical dose.

## Environmental Assessment

- Most INDs qualify for categorical exclusion under 21 CFR 25.31(e)
- If claiming exclusion: cite the specific 21 CFR 25 provision with basis statement
- If exclusion does not apply: prepare assessment per 21 CFR Part 25 Subpart B

## Pitfalls and Checks

- **Verify FDA forms** — retrieve current Form 1571/1572 from fda.gov; versions update periodically
- **Phase-appropriate CMC** — do not over-document Phase I or under-document Phase III
- **Cross-reference internally** — protocol references to nonclinical data must cite specific IND section/page
- **GLP compliance** — pivotal safety studies require 21 CFR Part 58; flag and justify any non-GLP studies
- **No promotional language** — avoid unsupported efficacy claims; this is a scientific/regulatory document
- **Safety-first framing** — every section must demonstrate adequate basis for protecting human subjects
- **Confidential info** — mark trade secrets per 21 CFR 312.130 if sponsor requests
- **eCTD format** — for electronic submissions, organize per FDA eCTD Module 1–5 structure
- **Pre-IND feedback** — if a Type B pre-IND meeting occurred, address each FDA comment explicitly